ANIP ANI Pharmaceuticals Inc

$90.17

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.

Website: https://www.anipharmaceuticals.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1023024
Address
210 MAIN STREET WEST, BAUDETTE, MN, US
Valuation
Market Cap
$1.49B
P/E Ratio
nan
PEG Ratio
1.06
Price to Book
3.70
Performance
EPS
$-1.04
Dividend Yield
—
Profit Margin
-3.02%
ROE
-4.18%
Technicals
50D MA
$62.92
200D MA
$59.89
52W High
$70.48
52W Low
$52.50
Fundamentals
Shares Outstanding
22M
Target Price
$81.50
Beta
0.49

ANIP EPS Estimates vs Actual

● Estimated
● Actual

ANIP News & Sentiment

Sep 29, 2025 • Zacks Commentary NEUTRAL
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Sep 25, 2025 • Zacks Commentary NEUTRAL
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Humana Extends TailorCare Tie-Up to Enhance MA Member Health
HUM expands its TailorCare partnership to Dallas and Denver, aiming to boost MA member health and cut MSK-related costs.
Sep 24, 2025 • Zacks Commentary BULLISH
Is ANI ( ANIP ) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Is Clover Health Investments ( CLOV ) Outperforming Other Medical Stocks This Year?
Here is how Clover Health Investments, Corp. (CLOV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Sentiment Snapshot

Average Sentiment Score:

0.414
50 articles with scored sentiment

Overall Sentiment:

Bullish

ANIP Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.84 Surprise
  • Reported EPS: $-0.55
  • Estimate: $0.29
  • Whisper: —
  • Surprise %: -287.5%
Nov 08, 2024
Sep 30, 2024 (Pre market)
0.25 Surprise
  • Reported EPS: $1.34
  • Estimate: $1.09
  • Whisper: —
  • Surprise %: 22.9%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.07 Surprise
  • Reported EPS: $1.02
  • Estimate: $0.95
  • Whisper: —
  • Surprise %: 7.4%
May 10, 2024
Mar 31, 2024 (Pre market)
0.21 Surprise
  • Reported EPS: $1.21
  • Estimate: $1.00
  • Whisper: —
  • Surprise %: 21.0%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.14 Surprise
  • Reported EPS: $1.00
  • Estimate: $0.86
  • Whisper: —
  • Surprise %: 16.3%
Nov 08, 2023
Sep 30, 2023 (Pre market)
0.43 Surprise
  • Reported EPS: $1.27
  • Estimate: $0.84
  • Whisper: —
  • Surprise %: 51.2%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.6 Surprise
  • Reported EPS: $1.28
  • Estimate: $0.68
  • Whisper: —
  • Surprise %: 88.2%
May 08, 2023
Mar 31, 2023 (Pre market)
0.82 Surprise
  • Reported EPS: $1.17
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 234.3%
Mar 09, 2023
Dec 31, 2022 (Pre market)
0.09 Surprise
  • Reported EPS: $0.76
  • Estimate: $0.67
  • Whisper: —
  • Surprise %: 13.4%

Financials